Hyftor

Sirolimus, the active ingredient in Hyftor, is an mTOR inhibitor presented as a topical formulation for cutaneous use. It modulates cellular proliferation and inflammation, making it suitable for managing dermatologic conditions and for systemic immunosuppression in transplant patients.

GNH USA supplies Hyftor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide through reliable cold‑chain logistics where required.

Hyftor (sirolimus) acts on the mTOR pathway and is employed in several immunologic and dermatologic indications. - Organ transplant rejection: helps prevent acute rejection by suppressing T‑cell activation. - Lymphangioleiomyomatosis (LAM): slows disease progression by inhibiting abnormal smooth‑muscle proliferation. - Graft‑versus‑host disease prophylaxis: reduces incidence of severe GVHD after hematopoietic stem‑cell transplantation. - Facial angiofibromas in tuberous sclerosis complex: diminishes lesion size and erythema when applied topically. - Kaposi sarcoma in immunocompromised patients: controls tumor growth by blocking angiogenesis.

Adverse reactions to Hyftor may vary in frequency and severity.

Common Side Effects: - Mouth ulcers: painful sores in the oral cavity. - Acneiform rash: pimples or pustular eruptions on the skin. - Hyperlipidemia: elevated cholesterol or triglyceride levels.

Serious or Rare Side Effects: - Severe infections: opportunistic bacterial, viral or fungal infections. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy: increased risk of certain cancers.

When prescribing Hyftor, clinicians should observe several precautionary measures to minimize risk. - Monitor blood counts: watch for leukopenia or anemia. - Assess lipid profile: check cholesterol and triglycerides regularly. - Evaluate liver function: perform hepatic enzyme tests before and during therapy. - Screen for infections: identify and treat active infections prior to initiation. - Adjust dose in renal impairment: reduce exposure in patients with decreased kidney function. - Store at room temperature: keep in original container, protect from moisture and light.

Hyftor may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase sirolimus levels. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic concentrations. - Concurrent use with other immunosuppressants (e.g., tacrolimus) without dose adjustment: raises risk of toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may modestly increase sirolimus exposure. - Macrolide antibiotics (e.g., erythromycin): can elevate drug levels. - Calcium channel blockers (e.g., diltiazem): may enhance sirolimus concentrations.